Mutant Myocilin Disease Model Patent Granted

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted Regeneron Pharmaceuticals, Inc. a patent (US12582104B2) for a mutant myocilin disease model. This patent covers non-human animal models engineered to express human myocilin, intended for assessing therapeutic reagents for glaucoma.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12582104B2 to Regeneron Pharmaceuticals, Inc. The patent covers novel non-human animal models, their genomes, and cells that comprise a humanized MYOC locus. These models are designed to express human or chimeric myocilin proteins and are intended for use in evaluating the efficacy of reagents targeting human myocilin, specifically for the treatment of glaucoma.

This patent grant is primarily of interest to pharmaceutical and biotechnology companies involved in glaucoma research and development. While it does not impose direct compliance obligations on regulated entities, it signifies intellectual property protection for specific research tools. Companies working on similar therapeutic approaches should be aware of this granted patent to navigate potential intellectual property landscapes and avoid infringement.

Source document (simplified)

← USPTO Patent Grants

Mutant myocilin disease model and uses thereof

Grant US12582104B2 Kind: B2 Mar 24, 2026

Assignee

Regeneron Pharmaceuticals, Inc.

Inventors

Gaurang Patel, Charleen Hunt, Yajun Tang, Qing Fang, Guochun Gong, Ying Hu, Carmelo Romano

Abstract

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized MYOC locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized MYOC locus express a human myocilin protein or a chimeric myocilin protein, fragments of which are from human myocilin. Methods are provided for using such non-human animals comprising a humanized MYOC locus to assess in vivo efficacy of human-myocilin-targeting reagents and reagents for treating glaucoma.